2. Anti-infection
  3. Bacterial
  4. Reutericyclin

Reutericyclin  (Synonyms: Reutericycline)

Cat. No.: HY-103249 Purity: 98.08%
COA
SDS
Handling Instructions Technical Support

Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections.

For research use only. We do not sell to patients.

Reutericyclin

Reutericyclin Chemical Structure

CAS No. : 303957-69-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Reutericyclin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections[1][2][3][4].

In Vitro

The MIC values of Reutericyclin for inhibiting and killing Clostridioides difficile strains 9689, BAA-1803 and BAA-1875 in logarithmic growth phase range from 0.09 to 0.19 mg/L, while its MBC values for the bacteria in stationary phase range from 0.19 to 0.5 mg/L[1].
Reutericyclin (200 mg/L) exhibits no cytotoxicity against Caco-2 colon cancer cells[1].
Reutericyclin (0.1-1.6 μg/mL) inhibits the growth of Methicillin (HY-121544)-susceptible and Methicillin-resistant clinical isolates of Staphylococcus aureus, with MIC50 values of 0.8 μg/mL and 3.12 μg/mL, and MIC90 values of 1.6 μg/mL and 6.25 μg/mL, respectively[3].
Reutericyclin (0.8-3.12 μg/mL) inhibits the growth of mupirocin (HY-B0958)-resistant clinical isolates of Staphylococcus aureus, with an MIC50 of 1.6 μg/mL and an MIC90 of 3.12 μg/mL[3].
Reutericyclin (0.012-0.4 μg/mL) inhibits the growth of clinical isolates of Streptococcus pyogenes, with an MIC50 of 0.4 μg/mL and an MIC90 of 0.4 μg/mL[3].
Reutericyclin shows no activity against Staphylococcus aureus in an environment containing 50% human serum, with an MIC of ≥200 μg/mL[3].
Reutericyclin (6.4 mg/L; 60 min; 600 MPa; 90 °C) induces a tailing effect during the inactivation of spores of Clostridium perfringens ATCC 7955 and Clostridium beijerinckii ATCC 8260, but shows no effect on spores of Bacillus amyloliquefaciens FAD 11/2[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reutericyclin Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: Caco-2 colonic carcinoma cells
Concentration: 200 mg/L
Incubation Time: 24 h
Result: Showed non-cytotoxic to Caco-2 colonic carcinoma cells, with >80% cell viability observed at a concentration of 200 mg/L.
In Vivo

Reutericyclin (2.5 μg per day; oral gavage; daily; 25 days) significantly mitigates Risperidone (HY-11018)-induced weight gain in female C57BL/6J mice, reducing average weight gain from 3.58 g to 2.5 g relative to risperidone-only treatment[2].
Reutericyclin (2.5 μg per day; oral gavage; daily; 50 days) restores energy efficiency and significantly reduces risperidone-induced weight gain in female C57BL/6J mice, even when co-administered with a reutericyclin-deficient L. reuteri mutant[2].
(R)-reutericyclin (2.5 μg per day; oral gavage; daily) mitigates risperidone-induced weight gain in female C57BL/6J mice, with efficacy lower than that of (S)-reutericyclin[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (female)[2]
Dosage: 2.5 μg per day
Administration: oral gavage; daily; 50 days
Result: Reduced average weight gain from ~8 g to ~4 g compared to risperidone-only treated mice (ANOVA, interaction p<0.05).
Restored energy efficiency to levels similar to vehicle control mice; risperidone-only treated mice had significantly higher energy efficiency compared to reutericyclin-treated cohorts (pairwise Mann-Whitney, p<0.05).
Showed no differences in food intake, water consumption, or digestive efficiency across groups.
Molecular Weight

349.46

Formula

C20H31NO4
CAS No.
Appearance

Solid

Color

Yellow to orange

SMILES

O=C1[C@@H](CC(C)C)N(C(/C=C/CCCCCCC)=O)C(O)=C1C(C)=O
Structure Classification
Initial Source

Lactobacillus reuteri

Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 33.33 mg/mL (95.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8616 mL 14.3078 mL 28.6156 mL
5 mM 0.5723 mL 2.8616 mL 5.7231 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (7.15 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (7.15 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 98.11%

SDS (254 KB)

COA (246 KB) HNMR (225 KB) LCMS (124 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.8616 mL 14.3078 mL 28.6156 mL 71.5389 mL
5 mM 0.5723 mL 2.8616 mL 5.7231 mL 14.3078 mL
10 mM 0.2862 mL 1.4308 mL 2.8616 mL 7.1539 mL
15 mM 0.1908 mL 0.9539 mL 1.9077 mL 4.7693 mL
20 mM 0.1431 mL 0.7154 mL 1.4308 mL 3.5769 mL
25 mM 0.1145 mL 0.5723 mL 1.1446 mL 2.8616 mL
30 mM 0.0954 mL 0.4769 mL 0.9539 mL 2.3846 mL
40 mM 0.0715 mL 0.3577 mL 0.7154 mL 1.7885 mL
50 mM 0.0572 mL 0.2862 mL 0.5723 mL 1.4308 mL
60 mM 0.0477 mL 0.2385 mL 0.4769 mL 1.1923 mL
80 mM 0.0358 mL 0.1788 mL 0.3577 mL 0.8942 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Reutericyclin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Reutericyclin303957-69-9ReutericyclineBacterialStaphylococcus epidermidisClostridium difficile infectionC57BL/6J miceCaco-2 colonic carcinoma cellsStaphylococcus aureusClostridium difficileLactobacillus sanfranciscensisstaphylococcal superficial skin infectionsClostridium spp.Gram-positive bacteriaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Reutericyclin
Cat. No.:
HY-103249
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (254 KB) Français - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Español - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.